Literature DB >> 20048208

Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community.

Renate B Schnabel1, Martin G Larson, Jennifer F Yamamoto, Lisa M Sullivan, Michael J Pencina, James B Meigs, Geoffrey H Tofler, Jacob Selhub, Paul F Jacques, Philip A Wolf, Jared W Magnani, Patrick T Ellinor, Thomas J Wang, Daniel Levy, Ramachandran S Vasan, Emelia J Benjamin.   

Abstract

BACKGROUND: Biomarkers of multiple pathophysiological pathways have been related to incident atrial fibrillation (AF), but their predictive ability remains controversial. METHODS AND
RESULTS: In 3120 Framingham cohort participants (mean age 58.4+/-9.7 years, 54% women), we related 10 biomarkers that represented inflammation (C-reactive protein and fibrinogen), neurohormonal activation (B-type natriuretic peptide [BNP] and N-terminal proatrial natriuretic peptide), oxidative stress (homocysteine), the renin-angiotensin-aldosterone system (renin and aldosterone), thrombosis and endothelial function (D-dimer and plasminogen activator inhibitor type 1), and microvascular damage (urinary albumin excretion; n=2673) to incident AF (n=209, 40% women) over a median follow-up of 9.7 years (range 0.05 to 12.8 years). In multivariable-adjusted analyses, the biomarker panel was associated with incident AF (P<0.0001). In stepwise-selection models (P<0.01 for entry and retention), log-transformed BNP (hazard ratio per SD 1.62, 95% confidence interval 1.41 to 1.85, P<0.0001) and C-reactive protein (hazard ratio 1.25, 95% confidence interval 1.07 to 1.45, P=0.004) were chosen. The addition of BNP to variables recently combined in a risk score for AF increased the C-statistic from 0.78 (95% confidence interval 0.75 to 0.81) to 0.80 (95% confidence interval 0.78 to 0.83) and showed an integrated discrimination improvement of 0.03 (95% confidence interval 0.02 to 0.04, P<0.0001), with 34.9% relative improvement in reclassification analysis. The combined analysis of BNP and C-reactive protein did not appreciably improve risk prediction over the model that incorporated BNP in addition to the risk factors.
CONCLUSIONS: BNP is a predictor of incident AF and improves risk stratification based on well-established clinical risk factors. Whether knowledge of BNP concentrations may be used to target individuals at risk of AF for more intensive monitoring or primary prevention requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20048208      PMCID: PMC3224826          DOI: 10.1161/CIRCULATIONAHA.109.882241

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  42 in total

1.  Homocysteine is unlikely to be associated with the risk of thromboembolic complications in atrial fibrillation.

Authors:  Sunil Nadar; Andrew Blann; Gregory Y H Lip
Journal:  Blood Coagul Fibrinolysis       Date:  2003-07       Impact factor: 1.276

2.  Raised plasma aldosterone and natriuretic peptides in atrial fibrillation.

Authors:  Ulrik Dixen; Lasse Ravn; Christian Soeby-Rasmussen; Anders Wallin Paulsen; Jan Parner; Erik Frandsen; Gorm B Jensen
Journal:  Cardiology       Date:  2006-09-12       Impact factor: 1.869

Review 3.  Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis.

Authors:  Tong Liu; Guangping Li; Lijian Li; Panagiotis Korantzopoulos
Journal:  J Am Coll Cardiol       Date:  2007-04-02       Impact factor: 24.094

4.  Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: an analysis from the breathing not properly multinational study.

Authors:  Cathrine W Knudsen; Paul Clopton; Arne Westheim; Tor Ole Klemsdal; Alan H B Wu; Philippe Duc; James McCord; Richard M Nowak; Judd E Hollander; Alan B Storrow; William T Abraham; Peter A McCullough; Alan S Maisel; Torbjørn Omland
Journal:  Ann Emerg Med       Date:  2005-06       Impact factor: 5.721

5.  Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study.

Authors:  S Stewart; C L Hart; D J Hole; J J McMurray
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

6.  Rising rates of hospital admissions for atrial fibrillation.

Authors:  Jens Friberg; Pernille Buch; Henrik Scharling; Niels Gadsbphioll; Gorm B Jensen
Journal:  Epidemiology       Date:  2003-11       Impact factor: 4.822

7.  Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention.

Authors:  Wendy A Wattigney; George A Mensah; Janet B Croft
Journal:  Circulation       Date:  2003-07-28       Impact factor: 29.690

8.  Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection.

Authors:  Renate Schnabel; Martin G Larson; Josée Dupuis; Kathryn L Lunetta; Izabella Lipinska; James B Meigs; Xiaoyan Yin; Jian Rong; Joseph A Vita; Christopher Newton-Cheh; Daniel Levy; John F Keaney; Ramachandran S Vasan; Gary F Mitchell; Emelia J Benjamin
Journal:  Hypertension       Date:  2008-04-21       Impact factor: 10.190

9.  Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures.

Authors:  Nancy R Cook; Paul M Ridker
Journal:  Ann Intern Med       Date:  2009-06-02       Impact factor: 25.391

10.  Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation.

Authors:  F Marín; V Roldán; V E Climent; A Ibáñez; A García; P Marco; F Sogorb; G Y H Lip
Journal:  Heart       Date:  2004-10       Impact factor: 5.994

View more
  116 in total

1.  A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women.

Authors:  David Conen; Paul M Ridker; Brendan M Everett; Usha B Tedrow; Lynda Rose; Nancy R Cook; Julie E Buring; Christine M Albert
Journal:  Eur Heart J       Date:  2010-05-25       Impact factor: 29.983

Review 2.  Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling.

Authors:  Fadia Mayyas; Karem H Alzoubi; David R Van Wagoner
Journal:  Int J Cardiol       Date:  2013-08-15       Impact factor: 4.164

Review 3.  Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure.

Authors:  Claire Sweeney; Fiona Ryan; Mark Ledwidge; Cristin Ryan; Ken McDonald; Chris Watson; Rebabonye B Pharithi; Joe Gallagher
Journal:  Cochrane Database Syst Rev       Date:  2019-10-15

Review 4.  Expert opinion paper on atrial fibrillation detection after ischemic stroke.

Authors:  Karl Georg Haeusler; Klaus Gröschel; Martin Köhrmann; Stefan D Anker; Johannes Brachmann; Michael Böhm; Hans-Christoph Diener; Wolfram Doehner; Matthias Endres; Christian Gerloff; Hagen B Huttner; Manfred Kaps; Paulus Kirchhof; Darius Günther Nabavi; Christian H Nolte; Waltraud Pfeilschifter; Burkert Pieske; Sven Poli; Wolf Rüdiger Schäbitz; Götz Thomalla; Roland Veltkamp; Thorsten Steiner; Ulrich Laufs; Joachim Röther; Rolf Wachter; Renate Schnabel
Journal:  Clin Res Cardiol       Date:  2018-04-27       Impact factor: 5.460

5.  Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes.

Authors:  A Mantovani; R Rigolon; I Pichiri; M Pernigo; C Bergamini; G Zoppini; E Bonora; G Targher
Journal:  J Endocrinol Invest       Date:  2015-07-16       Impact factor: 4.256

6.  N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort.

Authors:  Mary Cushman; Suzanne E Judd; Virginia J Howard; Brett Kissela; Orlando M Gutiérrez; Nancy S Jenny; Ali Ahmed; Evan L Thacker; Neil A Zakai
Journal:  Stroke       Date:  2014-04-22       Impact factor: 7.914

7.  Evaluation of Risk Prediction Models of Atrial Fibrillation (from the Multi-Ethnic Study of Atherosclerosis [MESA]).

Authors:  Joshua D Bundy; Susan R Heckbert; Lin Y Chen; Donald M Lloyd-Jones; Philip Greenland
Journal:  Am J Cardiol       Date:  2019-10-10       Impact factor: 2.778

8.  Body fat, body fat distribution, lean body mass and atrial fibrillation and flutter. A Danish cohort study.

Authors:  Lars Frost; Emelia J Benjamin; Morten Fenger-Grøn; Asger Pedersen; Anne Tjønneland; Kim Overvad
Journal:  Obesity (Silver Spring)       Date:  2014-02-18       Impact factor: 5.002

9.  Increased pericardial adipose tissue is correlated with atrial fibrillation and left atrial dilatation.

Authors:  Martin Greif; Franz von Ziegler; Reza Wakili; Janine Tittus; Christoph Becker; Susanne Helbig; Ruediger P Laubender; Wolfgang Schwarz; Melvin D'Anastasi; Jan Schenzle; Alexander W Leber; Alexander Becker
Journal:  Clin Res Cardiol       Date:  2013-04-13       Impact factor: 5.460

10.  Understanding increments in model performance metrics.

Authors:  Michael J Pencina; Ralph B D'Agostino; Joseph M Massaro
Journal:  Lifetime Data Anal       Date:  2012-12-16       Impact factor: 1.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.